Tania Fleitas Kanonnikoff

El 29 de abril el Dr. Filippo Pietrantonio, de la Unidad de Oncología Gastrointestinal en @IstTumori, impartirá el seminario 'Novel strategies in gastric cancer: moving from additive effect to synergistic combos'. 🕛8:15 h 📍Salón Actos INCLIVA y online form.typeform.com/to/SQVmWAHt

@gasclinicbcn @MoreiraR_Leti Felicidades 🎉!!!

📣La Dra. Glòria Fernández Esparrach és nomenada Acadèmica Corresponent de la Reial Acadèmia de Medicina de Catalunya ❗️ 👉 Un reconeixemen molt merescut que posa en valor la seva excel·lència en recerca, assistència, innovació i docència Enhorabona Glòria!

Great work led by M. Airoldi, with collaboration between Humanitas and INCLIVA–Hospital Clínico Valencia. pCR strongly predicts long‑term survival, and adjuvant chemo benefits non‑pCR patients, even poor responders. #GEA #Oncology #pCR doi.org/10.1016/j.esmo…

@incliva_iis Thanks so much for your support 🙏

🎗️ INCLIVA recibe un donativo de 4.269€ por parte del American School of Valencia, destinado a apoyar la investigación oncológica, gracias a la segunda edición de la #ASVFundRun, una carrera solidaria que movilizó a toda su comunidad educativa 🔗 incliva.es/incliva-recibe…

esmo.org/meeting-calend… “Join the ESMO Gastric Cancer Preceptorship and take the next step in your oncology journey.”

🔎How is the AIDA AI-Clinician trained? The AI-Clinician learns from real-world clinical experience captured in the @hpeureg registry. Using reinforcement learning, the AI trains like a physician, gaining experience. Ultimately, it recommends personalised first-line therapies.

As we welcome 2026, the AIDA consortium is incredibly proud of what we've accomplished together in 2025! This past year brought remarkable milestones. 🎉 First-ever webinar series, study publications, major conferences, media recognition, and more! See our 2025 journey!👇

Wishing you a joyful holiday season! 🎄 As we reflect with gratitude, we thank everyone who has been part of the AIDA journey, our team, collaborators, and supporters. Your contributions have pushed the boundaries of AI in advancing early detection of gastric cancer.

🎧 Podcast | ESMO 2025 – Upper GI cancers 👨‍⚕️ J. Dekervel with @ArndtVogel & E. O’Reilly 🧠 HCC: anti-TIGIT setbacks, periop IO+TKI, conversion surgery 🧬 Pancreatic: KRAS G12D inhibitors & ADCs on the horizon ⚖️ Promising signals, practice-changing? Not yet. 🔗 doi.org/10.1016/j.esmo… @OncoAlert

🎥 The final AIDA webinar is live! Miriam Cuatrecasas, Glória Fernández-Esparrach & Leticia Moreira explore precursor lesions of gastric cancer. 👉 Watch the full session with English subtitles: youtube.com/watch?v=OYjdYX…

It was our pleasure to host the autumn EORTC - European Organisation for Research and Treatment of Cancer GI group meeting in Valencia. Thanks to @LizzySmyth1 and Francesco Sclafani for their leadership and to all members for the great inputs and discussion.@EORTC @incliva_iis

Nuestro sincero agradecimiento de ❤️ a @_SEOM y a los amigos y familiares de #retodeRober por la beca concedida a nuestro grupo para investigación en cáncer gástrico. Comprometidos con nuestros pacientes y la investigación. @incliva_iis @GVAclinic

🎧 New @myESMO GI podcast! Get the latest insights on upper GI cancers 🔑 updates on oesophageal & #gastric cancer from the #ESMOCongress 2025 @FilippoPietran4 @tfleitask 🔈Listen now: 🔗 open.spotify.com/episode/5DIaw6… 🔗 soundcloud.com/esmo-podcasts/… #Oncology #GIcancer #CancerResearch

Study reveals an AI system that achieved a 94.1% success rate in personalising H. pylori treatment. Researchers led by Dr @KirillVeselkov from @imperialcollege have developed an AI Clinician system that tailors treatment. 🔗Further reading: imperial.ac.uk/news/266353/ai…

@MacarullaTeresa @EduardoTB94 Congratulations! Well deserved

Congratulations @EduardoTB94 for the Best Poster prize at #ESMO25👏👏👏👏

Happy #LegacyH2020 reunion at #ESMO Berlin 2025! 😀 with Sarah Derks, Andres Cervantes, Rodrigo Dientsmann, Maria Alsina!

We have seen the mountain ⛰️ top! MATTERHORN OS #ESMO25 OS continues to ⬆️over time (~7% 3y) Benefit independent of PD-L1 Enough now to adopt as SOC? #ESMOAmbassadors

📌New in @ESMO_Open: 🎯Tumor Boards can guide matched therapies for ESCAT II-III alterations. Patients had median OS 31 vs 11 months. 🏥Study conducted at @incliva_iis @GVAsanitat, led by @Desam_Roda @ValeGambardella 🔗sciencedirect.com/science/articl…

🌍 On #WorldCancerResearchDay we highlight Prof. Tamara Matysiak-Budnik (CHU de Nantes, AIDA partner): 🗣️ “To improve prevention & early detection of gastric cancer, we must better understand its mechanisms—only research, clinical & fundamental, can achieve this.”